Literature DB >> 27216011

Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.

Andrew P Loehrer1, Cristina R Ferrone.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is increasingly common and a leading cause of cancer-related mortality. Surgery remains the only possibility for cure. Upwards of 40% of patients present with locally advanced PDAC (LA-PDAC), where management strategies continue to evolve. In this review, we highlight current trends in neoadjuvant chemotherapy, surgical resection, and other multimodality approaches for patients with LA-PDAC. Despite promising early results, additional work is needed to more accurately and appropriately tailor treatment for patients with LA-PDAC.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27216011     DOI: 10.1159/000445020

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  4 in total

1.  Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.

Authors:  Geoffrey M Kozak; Jeffrey D Epstein; Sandeep P Deshmukh; Benjamin B Scott; Scott W Keith; Harish Lavu; Charles J Yeo; Jordan M Winter
Journal:  J Gastrointest Surg       Date:  2017-11-14       Impact factor: 3.452

2.  Kidney Transplantation after Extended Multivisceral Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Hryhoriy Lapshyn; Louisa Bolm; Martin Nitschke; Andreas M Luebke; Jakob R Izbicki; Yogesh K Vashist; Tobias Keck; Ulrich F Wellner
Journal:  Case Rep Transplant       Date:  2018-07-26

3.  A combination of platelet-to-lymphocyte ratio and carbohydrate antigen 19-9 predict early recurrence after resection of pancreatic ductal adenocarcinoma.

Authors:  Shinichi Ikuta; Takashi Sonoda; Tsukasa Aihara; Naoki Yamanaka
Journal:  Ann Transl Med       Date:  2019-09

4.  The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.

Authors:  Woo Hyun Paik; Yong Tae Kim
Journal:  J Korean Med Sci       Date:  2016-09       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.